- conflicts or gaps
- [[{"field": {"value": "identity.hq_location", "source_urls": ["https://www.ycombinator.com/companies/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335", "https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc"]}, "issue": {"value": "YC lists San Francisco; SBIR.gov lists Palo Alto (2627 Hanover St); inknowvation lists Hayward (3944 Trust Way). Company has had multiple California addresses since founding.", "source_urls": ["https://www.ycombinator.com/companies/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335", "https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc"]}}, {"field": {"value": "employees.snapshots", "source_urls": ["https://www.ycombinator.com/companies/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335", "https://www.linkedin.com/company/intact-therapeutics", "https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc"]}, "issue": {"value": "Headcount varies: YC team_size 4; SBIR.gov and LinkedIn 3; inknowvation employee range 5-9.", "source_urls": ["https://www.ycombinator.com/companies/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335", "https://www.linkedin.com/company/intact-therapeutics", "https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://www.cbinsights.com/company/intact-therapeutics/financials", "https://www.linkedin.com/company/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335"]}, "issue": {"value": "CB Insights reports $370K total; LinkedIn reports $770K; SBIR.gov alone confirms $1,521,257 in federal awards. No primary-source disclosure of equity round sizes (Y Combinator, Brightstone, Mehta Ventures, Encube Ethicals).", "source_urls": ["https://www.cbinsights.com/company/intact-therapeutics/financials", "https://www.linkedin.com/company/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335"]}}, {"field": {"value": "funding.sbir_phase_ii_count", "source_urls": ["https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc", "https://www.sbir.gov/portfolio/1503335"]}, "issue": {"value": "inknowvation lists 0 Phase II awards and $521,474 total; SBIR.gov lists 1 Phase II award ($999,783) and $1,521,257 total awarded.", "source_urls": ["https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc", "https://www.sbir.gov/portfolio/1503335"]}}, {"field": {"value": "funding.investors", "source_urls": ["https://www.cbinsights.com/company/intact-therapeutics/financials", "https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting"]}, "issue": {"value": "Investor naming varies: CB Insights lists Brightstone Venture Capital and Mehta Ventures; Processa press release lists Encube Ethicals and Brightstone Capital.", "source_urls": ["https://www.cbinsights.com/company/intact-therapeutics/financials", "https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting"]}}, {"field": {"value": "products.PCS12852", "source_urls": ["https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting", "https://www.sec.gov/Archives/edgar/data/1533743/000149315226007469/0001493152-26-007469.txt"]}, "issue": {"value": "June 2025 Processa term sheet contemplated licensing PCS12852 into Intact pipeline; definitive license never executed and term sheet expired 2026-02-12. PCS12852 status with Intact therefore unresolved in public filings.", "source_urls": ["https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/form8-k.htm", "https://www.sec.gov/Archives/edgar/data/1533743/000149315226007469/0001493152-26-007469.txt"]}}, {"field": {"value": "funding.non_dilutive_grants_mentioned", "source_urls": ["https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting", "https://www.sbir.gov/portfolio/1503335"]}, "issue": {"value": "Processa press release cites California Institute of Regenerative Medicine grants; no CIRM awards found in SBIR.gov portfolio or inknowvation records checked.", "source_urls": ["https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting", "https://www.sbir.gov/portfolio/1503335"]}}, {"field": {"value": "founders.founding_year", "source_urls": ["https://biodesign.stanford.edu/our-impact/technologies/intact.html", "https://www.ycombinator.com/companies/intact-therapeutics"]}, "issue": {"value": "Stanford Biodesign profile notes Pamnani co-founded Intact in 2017; YC and SBIR.gov list company founded 2015.", "source_urls": ["https://biodesign.stanford.edu/our-impact/technologies/intact.html", "https://www.ycombinator.com/companies/intact-therapeutics", "https://www.sbir.gov/portfolio/1503335"]}}]]
- source urls
- ["https://biodesign.stanford.edu/our-impact/technologies/intact.html", "https://intacttherapeutics.com/", "https://med.stanford.edu/profiles/sidhartha-sinha", "https://theorg.com/org/intact-therapeutics/org-chart/ravi-pamnani", "https://www.cbinsights.com/company/intact-therapeutics/financials", "https://www.inknowvation.com/sbir/companies/intact-therapeutics-inc", "https://www.linkedin.com/company/intact-therapeutics", "https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/137/processa-pharmaceuticals-signs-binding-term-sheet-granting", "https://www.processapharmaceuticals.com/investors/sec-filings/all-sec-filings/xbrl_doc_only/2962", "https://www.sbir.gov/awards/178005", "https://www.sbir.gov/awards/202976", "https://www.sbir.gov/awards/207816", "https://www.sbir.gov/portfolio/1503335", "https://www.sec.gov/Archives/edgar/data/1533743/000149315226007469/0001493152-26-007469.txt", "https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/form8-k.htm", "https://www.ycombinator.com/companies/intact-therapeutics"]